Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and ApoA-I in response to inflammation in human ApoA-I transgenic mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 7, 2002, Pages 1213-1218

  Tietge, Uwe J F ^a   Maugeais, Cyrille ^a   Lund Katz, Sissel ^b   Grass, David ^c   DeBeer, Frederick C ^d   Rader, Daniel J ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Xenogen Biosciences   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apolipoproteins; HDL; Inflammation; Lipoproteins; Phospholipase

Indexed keywords

ACUTE PHASE PROTEIN; APOLIPOPROTEIN A1; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; PHOSPHOLIPASE A2; PHOSPHOLIPID; SERUM AMYLOID A; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; GEL ELECTROPHORESIS; GEL FILTRATION; GENE OVEREXPRESSION; GENE TRANSFER; INFLAMMATION; LIPID BLOOD LEVEL; LIVER; MOUSE; NONHUMAN; PARTICLE SIZE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CROSSES, GENETIC; ENDOTOXINS; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOLIPASES A; SERUM AMYLOID A PROTEIN; SUBSTRATE SPECIFICITY; UP-REGULATION;

EID: 0036061703     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000023228.90866.29     Document Type: Article

References (31)

1. High-density lipoprotein: The clinical implications of recent studies
2. Isolated low HDL-cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men
3. Serum amyloid A and high density lipoproteins during the acute phase response
4. Further studies on serum lipoproteins in connective tissue disease
5. The mortality of rheumatoid arthritis
6. Atherosclerosis: An inflammatory disease
7. Inflammatory markers of coronary risk
8. Diversity of group types, regulation and function of phospholipase A2
9. Phospholipases A2
10. A reassessment of the low molecular weight phospholipase A2 gene family in mammals
11. Enhanced expression of group II phospholipase A2 genes in the tissues of endotoxin shocked rats and its suppression of glucocorticoid
12. Serum phospholipase A2 in inflammatory diseases
13. Phospholipase A2 correlates with disease activity in rheumatoid arthritis
14. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease
15. Role of group II secretory phospholipase A2 in atherosclerosis, I: Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2
16. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I
17. Effects of endotoxin and cytokines on lipid metabolism
18. Serum amyloid A (SAA): An acute phase protein and apolipoprotein
19. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL-cholesterol or apoA-I levels in human apoA-I transgenic mice
20. Serum amyloid A protein enhances the activity of secretory phospholipase A2
21. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains
22. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate
23. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
24. Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters
25. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I
26. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models
27. Human apolipoprotein A-I and A-II metabolism
28. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size
29. In vivo protection against endotoxin by plasma high density lipoprotein
30. Protection by group II phospholipase A2 against staphylococcus aureus
31. Serum amyloid A-containing human high density lipoprotein 3: Density, size, and apolipoprotein composition